KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study

Molecular Diagnosis and Therapy

Volumn 20, Issue 1, 2016, Pages 65-74

  Dadduzio, Vincenzo ^a   Basso, Michele ^a   Rossi, Sabrina ^a   Cenci, Tonia ^a   Capodimonti, Sara ^a   Strippoli, Antonia ^a   Orlandi, Armando ^a   Cerchiaro, Eleonora ^a   Schinzari, Giovanni ^a   Cassano, Alessandra ^a   Martini, Maurizio ^a   Barone, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; CODON; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL PRACTICE; CODON; COLORECTAL CANCER; EXON; FEMALE; GENE MUTATION; HUMAN; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; VERY ELDERLY; WILD TYPE; BIOASSAY; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MUTATION; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CODON; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES;

EID: 84956668594     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-015-0178-8     Document Type: Article

References (28)

1. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;1989(49):4682–9.
2. Schubbert S, Shannon K, Bollag G. Hyperactive ras in developmental disorders and cancer. Nat Rev Cancer. 2007;2007(7):295–308.
3. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–32.
4. Andreyev HJN, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten Ras mutations in patients with colorectal cancer: the multicenter ‘RASCAL’ study. J Natl Cancer Inst. 1998;90(9):675–84.
5. Roock WD, Vriendt VD, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;2011(12):594–603.
6. Douillard JY, Oliner KS, Siena S, Tabernero J. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34. doi:10.1056/NEJMoa1305275.
7. Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, De Gregorio V, Giannini R, Basolo F, Masi G, Falcone A. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 2015;136(1):83–90. doi:10.1002/ijc.28955(Epub 2014 May 28).
8. Peeters M, Douillard JY, Van Cutsem E, Siena S. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer, assessment as prognostic and predictive biomarkers of response to Panitumumab. J Clin Oncol. 2012;2012(31):759–65.
9. Van Cutsem E, Kohne CH, Lang I, Folprecht G. Cetuximab plus irinotecan, fluorouracil and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;2011(29):2011–9.
10. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104(5):856–62.
11. Al-Mulla F, Milner-White EJ, Going JJ, Birnie GD. Structural differences between valin-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol. 1999;1999(187):433–8.
12. Guerrero S, Casanova I, Farrè L, Mazo A, Capellà G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000;2000(60):6750–6.
13. Andreyev HJN, Norman AR, Cunningham D, Oates J, Dix BR. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001;85(5):692–6.
14. Imamura Y, Morikawa T, Liao X, Lockhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012;18(17):4753–63. doi:10.1158/1078-0432.CCR-11-3210.
15. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000;9(11):1193–7.
16. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103–14. doi:10.1016/S0140-6736(11)60613-2.
17. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Barni S. KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. Med Oncol. 2013;2013(30):650.
18. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22(7):1535–46. doi:10.1093/annonc/mdq632.
19. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V. Fluorouracil, Leucovorin, and Irinotecan plus Cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33(7):692–700. doi:10.1200/JCO.2014.59.4812.
20. Stintzing S, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Held S, Giessen C, Moehler M, Jagenburg A, Jung A, Kirchner T, Heinemann V. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population. ESMO 2014 Congress, Proffered Paper Session—ref. LBA11; 2014.
21. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–7. doi:10.1200/JCO.2013.53.2473.
22. Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony MR, O’Neil BH, Shaw JE, Polite B, Hochster H, Atkins J, Goldberg R, Mayer R, Schilsky R, Bertagnolli M, Venook A. CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC)—ESMO 2014 Congress, Proffered Paper Session—ref. 501O; 2014.
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. doi:10.1016/j.ejca.2008.10.026.
24. Bruera G, Cannita K, Tessitore A, Russo A, Alesse E, Ficorella C, Ricevuto E. The prevalent KRAS exon 2 c.35G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? Crit Rev Oncol Hematol. 2015;93(3):190–202. doi:10.1016/j.critrevonc.2014.10.004.
25. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005;23(36):9441–2.
26. Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, Shirasawa S, Sasazuki T. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995;1995(55):4575–80.
27. Venook A, Niedzwiecki D, Lenz H, Mahoney M, Innocenti F, O’Neil B, Hochster H, Goldberg R, Schilsky R, Mayer R, Polite B, Atkins J, Shaw JE, Bertagnolli M, Blanke C. CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy. ESMO 2014 Congress, Proffered Paper Session—ref. LBA10; 2014.
28. Renaud S, Romain B, Falcoz PE, Olland A, Santelmo N, Brigand C, Rohr S, Guenot D, Massard G. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer. 2015;112(4):720–8. doi:10.1038/bjc.2014.499.